Next Article in Journal
Why Ubiquitin Has Not Evolved
Next Article in Special Issue
Prognostic Value of RNASEH2A-, CDK1-, and CD151-Related Pathway Gene Profiling for Kidney Cancers
Previous Article in Journal
The Beneficial Effects of Allicin in Chronic Kidney Disease Are Comparable to Losartan
Previous Article in Special Issue
Magnetically Bioprinted Human Myometrial 3D Cell Rings as A Model for Uterine Contractility
Open AccessArticle

Identification of Circulating miRNAs Differentially Regulated by Opioid Treatment

1
Clinical Pharmacology Department, Daiichi Sankyo Co., Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710, Japan
2
Biomarker Research Department, Daiichi Sankyo Co., Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710, Japan
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2017, 18(9), 1991; https://doi.org/10.3390/ijms18091991
Received: 31 August 2017 / Revised: 12 September 2017 / Accepted: 13 September 2017 / Published: 16 September 2017
(This article belongs to the Collection Precision Medicine—From Bench to Bedside)
Emerging evidence demonstrates functional contributions of microRNAs (miRNAs) to μ-opioid receptor (MOR) signaling, but the information so far has been mostly limited to their intracellular regulatory mechanisms. The present study aimed to investigate changes in plasma miRNA profiles elicited by opioid treatment in blood samples collected from clinical studies. Healthy male subjects were orally administered with hydromorphone or oxycodone and blood samples were collected at a specified time after the drug treatment. A total of 179 plasma miRNAs were measured using multiplex qRT-PCR. Nine and seventeen miRNAs were commonly upregulated (let-7a-5p, miR-423-3p, miR-199a-3p, miR-146a-5p, miR-23b-3p, miR-24-3p, miR-221-3p, miR-223-3p, and miR-146b-5p) and downregulated (miR-144-3p, miR-215, miR-363-3p, etc.), respectively, following opioid treatment. The MOR signaling-associated miRNAs, namely let-7 family miRNAs (i.e., let-7d-5p, let-7f-5p, let-7c, let-7e-5p), miR-103a-3p, miR-339-3p, miR-146a-5p, miR-23b-3p, miR-23a-3p, and miR-181a-5p, were differentially expressed following drug treatment. These differentially expressed miRNAs are circulating biomarker candidates that can be used to evaluate MOR stimulation and serve as novel clinical diagnostic tools for improving clinical outcomes. View Full-Text
Keywords: hydromorphone; oxycodone; μ-opioid receptor; microRNA; biomarker; qRT-PCR hydromorphone; oxycodone; μ-opioid receptor; microRNA; biomarker; qRT-PCR
Show Figures

Graphical abstract

MDPI and ACS Style

Toyama, K.; Kiyosawa, N.; Watanabe, K.; Ishizuka, H. Identification of Circulating miRNAs Differentially Regulated by Opioid Treatment. Int. J. Mol. Sci. 2017, 18, 1991.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop